Literature DB >> 7514446

Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study.

R H Simon1, J F Engelhardt, Y Yang, M Zepeda, S Weber-Pendleton, M Grossman, J M Wilson.   

Abstract

In preparation for human trials of gene therapy for cystic fibrosis (CF), we performed a preclinical study of gene transfer into the lungs of baboons. Recombinant adenovirus vectors containing expression cassettes for human cystic fibrosis transmembrane conductance regulator (CFTR) and Escherichia coli beta-galactosidase (lacZ) were instilled through a bronchoscope into limited regions of lung in 14 baboons. A detailed accounting of the extent, distribution, and duration of gene expression is contained in a companion article (Engelhardt et al., 1993b). In this article, we report the results of toxicity studies in which clinical laboratory tests, chest radiographs, and necropsy studies were used to detect adverse effects. The only adverse effect noted was a mononuclear cell inflammatory response within the alveolar compartment of animals receiving doses of virus that were required to induce detectable gene expression. Minimal inflammation was seen at 10(7) and 10(8) pfu/ml, but at 10(9) and more prominently at 10(10) pfu/ml, a perivascular lymphocytic and histiocytic infiltrate was seen. The intensity of inflammation increased between 4 and 21 days. At its greatest intensity, there was diffuse alveolar wall damage with intra-alveolar edema. Airways were relatively spared, despite the intensity of alveolar inflammation. Clinical tests did not accurately reflect the presence of lung inflammation, with the exception of chest radiographs which revealed alveolar infiltrates, but only in regions of lung having the greatest intensity inflammation. We conclude that adenovirus-mediated gene transfer into the lungs of baboons is associated with development of alveolar inflammation at high doses of virus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7514446     DOI: 10.1089/hum.1993.4.6-771

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  51 in total

1.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

Review 3.  The potential for stem cell therapy in cystic fibrosis.

Authors:  Helen Spencer; Adam Jaffe
Journal:  J R Soc Med       Date:  2004       Impact factor: 5.344

4.  Adenoviral-mediated gene transfer to fetal pulmonary epithelia in vitro and in vivo.

Authors:  P B McCray; K Armstrong; J Zabner; D W Miller; G A Koretzky; L Couture; J E Robillard; A E Smith; M J Welsh
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 5.  Gene therapy for cystic fibrosis: challenges and future directions.

Authors:  J M Wilson
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.

Authors:  S Kochanek; P R Clemens; K Mitani; H H Chen; S Chan; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

7.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Adenovirus-mediated transfer of the HST-1 (FGF4) gene induces increased levels of platelet count in vivo.

Authors:  H Sakamoto; T Ochiya; Y Sato; M Tsukamoto; H Konishi; I Saito; T Sugimura; M Terada
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 9.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

10.  Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.

Authors:  M I Gorziglia; M J Kadan; S Yei; J Lim; G M Lee; R Luthra; B C Trapnell
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.